Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), and Translational Research Informatics Center (TRI), in the name of Foundation for Biomedical Research and Innovation (FBRI), committed to promote academic translational researches in Japan, announce today an international cooperation agreement to introduce French biomedical- related patents to the Japanese market.

Such collaboration will be developed through translational activities which leads to the results from the basic research to the clinical practice and focus on the promotion of the potential license agreements with companies from the Japanese life science industry.

This international alliance marks a significant milestone in strengthening relationships between Inserm Transfert and TRI, two structures from Academia with a prime mission of transferring to the industry for the patients sake. Both stakeholders share the same vision that a comprehensive worldwide eco-system in translational research in the field of biomedical research, is the best way to accelerate the path from scientific achievements to patients.

Each partner brings unique strengths to the collaboration: TRI's expertise in the support of innovation of medical technologies and data center and statistical center management, by facilitating the transfer of medical research findings or inventions to clinical practice will be seamlessly coupled with Inserm Transfert know-how to source innovative inventions from the Inserm laboratories, to set-up collaboration schemes with industrials, and to present a large range of licensing opportunities.

Complementing each other, the mutual interactions offer opportunities to foster biomedical inventions in the Japanese market and develop them at an international level.

licensing of Inserm patents, and be able to introduce inventions of Inserm to Japanese universities and pharmaceutical companies. We believe that our relationship contributes to accelerate translational research in Japan. TRI and Inserm Transfert are looking forward to further the collaboration in the future so that the Japanese academia oriented patents can be introduced worldwide. This must lead the inventions arising from Japanese academia to the global exposure."